01
Clinical
Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy
A preclinical study maps the immunodominance hierarchy of endogenous neoantigens in the BBN963 bladder cancer model. Using high-throughput ELISpot, researchers found that anti-PD-1 and anti-CTLA-4 therapies do not substantially reshape this hierarchy, suggesting stable antigen targets for vaccine design regardless of checkpoint inhibition status.